- Home
- MRCC vs OBIO Comparison
MRCC vs OBIO Comparison
Compare MRCC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- OBIO
- Stock Information
- Founded
- MRCC 2011
- OBIO 2017
- Country
- MRCC United States
- OBIO United States
- Employees
- MRCC N/A
- OBIO N/A
- Industry
- MRCC Investment Managers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- MRCC Finance
- OBIO Health Care
- Exchange
- MRCC Nasdaq
- OBIO Nasdaq
- Market Cap
- MRCC 174.8M
- OBIO 200.1M
- IPO Year
- MRCC 2012
- OBIO N/A
- Fundamental
- Price
- MRCC $8.21
- OBIO $4.94
- Analyst Decision
- MRCC Strong Buy
- OBIO Strong Buy
- Analyst Count
- MRCC 1
- OBIO 4
- Target Price
- MRCC $9.00
- OBIO $15.75
- AVG Volume (30 Days)
- MRCC 71.5K
- OBIO 53.8K
- Earning Date
- MRCC 11-12-2024
- OBIO 11-12-2024
- Dividend Yield
- MRCC 12.15%
- OBIO N/A
- EPS Growth
- MRCC 298.01
- OBIO N/A
- EPS
- MRCC 0.60
- OBIO N/A
- Revenue
- MRCC $62,007,000.00
- OBIO $2,647,000.00
- Revenue This Year
- MRCC N/A
- OBIO $12.39
- Revenue Next Year
- MRCC N/A
- OBIO $120.99
- P/E Ratio
- MRCC $13.71
- OBIO N/A
- Revenue Growth
- MRCC N/A
- OBIO N/A
- 52 Week Low
- MRCC $6.77
- OBIO $4.22
- 52 Week High
- MRCC $8.74
- OBIO $10.46
- Technical
- Relative Strength Index (RSI)
- MRCC 42.18
- OBIO 40.52
- Support Level
- MRCC $8.37
- OBIO $5.05
- Resistance Level
- MRCC $8.66
- OBIO $5.84
- Average True Range (ATR)
- MRCC 0.19
- OBIO 0.44
- MACD
- MRCC -0.05
- OBIO -0.05
- Stochastic Oscillator
- MRCC 1.85
- OBIO 12.12
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.